Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 5 years - Fox, E J; Arnold, D J; Cohen, J A
Poster session presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 7–10, 2015; Barcelona, Spain